Here are the most-read “5 things” articles from 2025.

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single ...

If you ever happen to encounter a herd of Mangalica pigs on a foggy morning, you might think you had stumbled onto a sheep ...

If you want grass-fed ground beef that browns properly and doesn't blow the budget, Walmart's Marketside 80/20 grass-fed and ...

The latest announcement is out from Invivyd ( (IVVD) ).

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...

Testosterone replacement therapy (TRT) is linked to a significantly lower risk of major CV events in men with secondary hypogonadism.

Investing.com -- Invivyd shares rose about 2.4% in premarket trading after the company announced that the U.S. Food and Drug Administration has granted Fast Track designation for its COVID-19 ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back PainPHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical ...

Christmas is here and with it the moments of disconnection and rest, including from the gym and sports. And, although it is ...